open orphan |

Open Orphan #ORPH – Positive results from RSV Human Challenge Study

RSV Human Challenge Study conducted by hVIVO yields positive results Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the announcement dated 1 September 2021 from Barvarian Nordic A/S (OMX: BAVA), reporting positive results received from a human […]

Alan Green talks Open Orphan #ORPH, Aquis #AQX & Ananda Developments #ANA

Alan Green talks Open Orphan #ORPH, Aquis #AQX & Ananda Developments #ANA

Researchers Infect Volunteers With Coronavirus, Hoping to Conquer Covid-19 – Wall Street Journal

By Jenny Strasburg Sept. 4, 2021 530 am ET LONDON—Much of the world spent the past year taking vaccines and wearing masks to evade Covid-19. In the U.K., almost four dozen volunteers have had the virus dripped into their noses by syringe in clinical experiments. So-called human challenge studies—which intentionally expose healthy people to viruses […]

WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials

U.K. company is growing the highly contagious variant under tight lab controls for use in challenge studies Scientists have coaxed the Delta strain to mature, said Andrew Catchpole, chief scientiic oficer of trial partner hVivo. PHOTO: HVIVO SERVICES LIMITED by Jenny Strasburg – Wall Street Journal LONDON—While the rest of the world is trying to […]

The Times – Drug Tester’s £8m Contract Win

Tom Howard Market Report – Open Orphan #ORPH shares rose after the AIM company bagged a new contract worth £8.1m with one of Europe’s biggest drugmakers… Link here to read the full Times article

Open Orphan #ORPH – £8.1m Asthma Human Challenge Study Contract Win

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed an £8.1m contract with a major global pharmaceutical company to test its inhaled human rhinovirus (hRV) antiviral product using […]

Open Orphan #ORPH – Development of Controlled Human Malaria Infection Human Challenge Study

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in testing vaccines and antivirals using human challenge clinical trials, announces that its subsidiary, hVIVO, has developed a Controlled Human Malaria Infection (“CHMI”) challenge model, both strengthening and further diversifying the Company’s world leading portfolio of viral challenge study models. […]

Open Orphan #ORPH – Pfizer successful Phase 2a human challenge trial

Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”. Although Pfizer have not mentioned Open Orphan by name and we have not formally announced […]

Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences […]